Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002967 · ClinicalTrials.gov registry record · Phase 3
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00002967 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The trial reports 20 study locations across 8 states.
The verdict
NCT00002967, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to study the effectiveness of tamoxifen, octreotide, and chemotherapy in treating women who have stage I or stage II breast cancer.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
- DRUG octreotide pamoate
Study Locations (20)
California
- Scripps Clinic and Research Foundation - La Jolla - La Jolla
- University of California San Diego Cancer Center - La Jolla
- Loma Linda University Medical Center - Loma Linda
- CCOP - Bay Area Tumor Institute - Oakland
- Sutter Cancer Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Kaiser Permanente Medical Center - Vallejo - Vallejo
Florida
- Baptist Regional Cancer Institute - Jacksonville - Jacksonville
- CCOP - Mount Sinai Medical Center - Miami Beach
- Ocala Oncology Center - Ocala
- MD Anderson Cancer Center Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
Alabama
- Baptist Medical Center - Birmingham - Birmingham
- Huntsville Hospital System - Huntsville
- MBCCOP - University of South Alabama - Mobile
Arizona
- CCOP - Greater Phoenix - Phoenix
Colorado
- CCOP - Colorado Cancer Research Program, Inc. - Denver
Connecticut
- Hartford Hospital - Hartford
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Georgia
- Winship Cancer Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002967
The ClinicalTrials.gov registry entry for NCT00002967 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00002967 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00002967 about?
NCT00002967 is a clinical study titled "Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to study the effectiveness of tamoxifen, octreotide, and chemotherapy in...
What is the current status of trial NCT00002967?
This trial is currently completed. It is a Phase 3 study. The study started on 1997-05. Estimated completion is 2006-03.
What conditions does trial NCT00002967 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00002967?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG), octreotide pamoate (DRUG).
Who is sponsoring clinical trial NCT00002967?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002967 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.